Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade B 21.48 -1.15% -0.25
CLVS closed down 1.15 percent on Tuesday, December 11, 2018, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CLVS trend table...

Date Alert Name Type % Chg
Dec 11 Calm After Storm Range Contraction 0.00%
Dec 11 Stochastic Reached Overbought Strength 0.00%
Dec 11 Upper Bollinger Band Walk Strength 0.00%
Dec 11 Wide Bands Range Expansion 0.00%
Dec 11 Overbought Stochastic Strength 0.00%
Dec 11 Upper Bollinger Band Touch Strength 0.00%
Dec 10 MACD Bullish Centerline Cross Bullish -1.15%
Dec 10 Calm After Storm Range Contraction -1.15%
Dec 10 Upper Bollinger Band Walk Strength -1.15%
Dec 10 Wide Bands Range Expansion -1.15%

Older signals for CLVS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Is CLVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.02
52 Week Low 11.5
Average Volume 3,294,685
200-Day Moving Average 39.6816
50-Day Moving Average 20.8766
20-Day Moving Average 17.666
10-Day Moving Average 19.128
Average True Range 1.8719
ADX 29.51
+DI 31.9661
-DI 14.9832
Chandelier Exit (Long, 3 ATRs ) 17.2643
Chandelier Exit (Short, 3 ATRs ) 19.4957
Upper Bollinger Band 21.9004
Lower Bollinger Band 13.4316
Percent B (%b) 0.95
BandWidth 47.938413
MACD Line 0.3661
MACD Signal Line -0.5364
MACD Histogram 0.9025
Fundamentals Value
Market Cap 1.05 Billion
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -2.41
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.70
Resistance 3 (R3) 23.85 23.25 23.33
Resistance 2 (R2) 23.25 22.69 23.18 23.21
Resistance 1 (R1) 22.37 22.34 22.07 22.22 23.08
Pivot Point 21.77 21.77 21.63 21.70 21.77
Support 1 (S1) 20.89 21.21 20.59 20.74 19.88
Support 2 (S2) 20.29 20.86 20.22 19.75
Support 3 (S3) 19.41 20.29 19.63
Support 4 (S4) 19.26